Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Current Assets (2020 - 2026)

Maxcyte has reported Current Assets over the past 6 years, most recently at $118.4 million for Q4 2025.

  • Quarterly Current Assets fell 31.05% to $118.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $118.4 million through Dec 2025, down 31.05% year-over-year, with the annual reading at $118.4 million for FY2025, 31.05% down from the prior year.
  • Current Assets was $118.4 million for Q4 2025 at Maxcyte, down from $124.6 million in the prior quarter.
  • Over five years, Current Assets peaked at $270.4 million in Q4 2021 and troughed at $84.6 million in Q2 2021.
  • The 5-year median for Current Assets is $190.2 million (2023), against an average of $199.0 million.
  • Year-over-year, Current Assets skyrocketed 497.6% in 2021 and then crashed 31.05% in 2025.
  • A 5-year view of Current Assets shows it stood at $270.4 million in 2021, then dropped by 6.72% to $252.3 million in 2022, then fell by 24.61% to $190.2 million in 2023, then decreased by 9.73% to $171.7 million in 2024, then crashed by 31.05% to $118.4 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Current Assets are $118.4 million (Q4 2025), $124.6 million (Q3 2025), and $143.2 million (Q2 2025).